



August 07, 2017

The National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex
Mumbai 400051

Bombay Stock Exchange Limited
1st floor, Rotunda Building, Dalal Street
Fort, Mumbai 400001

Dear Sir/Madam,

Sub: Outcome of the Board meeting held today.

With reference to the above captioned subject, we are enclosing herewith a copy of un-audited Financial Results along with the Limited Review Report for the quarter ended June 30, 2017 as approved by the Board of Directors of the Company at its meeting held on August 07, 2017.

The Un-audited Financial Results will be published in the newspapers within the stipulated time as per the SEBI Listing Regulations.

Kindly take the same on record.

Thanking you,

**Yours faithfully,
For Merck Limited**

Vikas R. Gupta
General Counsel & Company Secretary
Encl : As above



Merck Limited

Registered Office
Godrej One, 8th Floor, Pirojshanagar
Eastern Express Highway, Vikhroli East
Mumbai 400079, India.
Phone +91 22 62109000
Fax +91 22 62109999
www.merck.co.in
CIN: L99999MH1967PLC013726

STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH JUNE, 2017

						(Rs in lakhs)
	Particulars	3 months ended 30/06/2017	3 months ended 31/03/2017	3 months ended 30/06/2016	Half Year ended 30/06/2017	Half Year ended 30/06/2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1.	Revenue from Operations					
	Sales	25,912.67	22,987.69	27,156.76	49,900.36	48,185.31
	Other operating income	654.69	704.51	515.48	1,359.19	1,041.19
	Total Revenue from Operations	26,567.35	23,692.20	27,672.24	50,259.55	49,226.50
2.	Other Income	540.10	671.53	664.59	1,211.63	1,209.70
3.	Total Income (1+2)	27,107.45	24,363.73	28,336.83	51,471.18	50,436.20
4.	Expenses					
	a) Cost of materials consumed	6,299.32	5,408.20	5,695.86	11,706.52	11,885.66
	b) Purchases of stock-in-trade	4,282.29	4,097.26	5,724.68	8,379.55	7,917.06
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	(27.09)	(479.15)	834.59	(606.24)	767.40
	d) Excise duty	761.72	797.38	1,032.12	1,549.10	1,874.92
	e) Employee benefits expense	4,153.69	4,096.41	3,941.54	8,250.00	7,447.47
	f) Finance Costs	-	-	-	-	-
	g) Depreciation and amortisation expense	644.79	623.40	623.30	1,269.19	1,248.38
	h) Other expenses	8,340.63	7,514.08	7,047.11	15,854.61	14,806.42
	Total expenses (4)	24,444.16	22,057.59	24,899.20	46,501.73	45,947.31
5.	Profit before exceptional items and tax (3-4)	2,663.30	2,306.15	3,437.63	4,969.45	4,488.89
6.	Exceptional items	-	-	-	-	-
7.	Profit before tax (5-6)	2,663.30	2,306.15	3,437.63	4,969.45	4,488.89
8.	Tax Expenses					
	Current Tax	1,038.00	1,062.00	1,000.00	2,100.00	1,700.00
	Deferred Tax	(937.31)	(239.55)	159.63	(625.65)	(329.22)
9.	Profit for the period (7-8)	2,012.61	1,482.70	2,278.00	3,495.31	3,118.11
10.	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss					
	i. Re-measurement (losses) on defined benefit plans	(60.34)	(56.10)	(23.28)	(116.44)	(45.53)
	ii. Income tax relating to items that will not be reclassified to profit or loss	20.87	19.42	8.06	40.30	15.76
	Total Other Comprehensive Income	(39.47)	(36.68)	(15.22)	(76.14)	(29.77)
11.	Total Comprehensive Income for the period (9+10)	1,973.14	1,446.02	2,262.78	3,419.17	3,088.34
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,659.94	1,659.94	1,659.94	1,659.94	1,659.94
13.	Earnings per equity share (of Rs 10/- each) (not annualised):					
	(a) Basic	12.12	8.93	13.72	21.06	18.78
	(b) Diluted	12.12	8.93	13.72	21.06	18.78

						(Rs in lakhs)
Sr. No.	Particulars	3 months ended 30/06/2017	3 months ended 31/03/2017	3 months ended 30/06/2016	Half Year ended 30/06/2017	Half Year ended 30/06/2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1.	Segment Revenue					
	a) Pharmaceuticals	20,471.70	18,914.63	21,557.00	39,286.23	38,478.35
	b) Chemicals	6,095.65	4,877.67	6,115.24	10,973.32	10,748.15
	Total	26,567.35	23,692.20	27,672.24	50,259.55	49,226.50
	Less : Inter segment revenue	-	-	-	-	-
	Revenue from operations (net)	26,567.35	23,692.20	27,672.24	50,259.55	49,226.50
2.	Segment Results (Profit before Tax and interest from each segment)					
	a) Pharmaceuticals	1,774.94	2,025.80	2,939.56	3,800.74	3,297.71
	b) Chemicals	607.44	(236.90)	569.04	370.54	673.44
	Total	2,382.38	1,788.90	3,508.60	4,171.28	3,971.15
	Less : Other un-allocable expenditure net of un-allocable income	(280.92)	(517.25)	70.97	(798.17)	(517.74)
	Total Profit before Tax	2,663.30	2,306.15	3,437.63	4,969.45	4,488.89
3.	Capital Employed					
	Segment Assets					
	Pharmaceuticals	34,366.82	35,290.21	28,774.48	34,366.82	28,774.48
	Chemicals	16,572.81	13,912.02	17,370.70	16,572.81	17,370.70
	Unallocated	39,385.62	41,811.71	34,553.54	39,385.62	34,553.54
	Total Assets	90,305.25	91,013.94	80,698.72	90,305.25	80,698.72
	Segment Liabilities					
	Pharmaceuticals	16,504.78	16,835.48	13,763.29	16,504.78	13,763.29
	Chemicals	4,386.21	4,502.70	4,590.91	4,386.21	4,590.91
	Unallocated	1,809.03	1,428.95	657.30	1,809.03	657.30
	Total Liabilities	22,700.02	22,767.13	19,011.50	22,700.02	19,011.50
	Capital Employed					
	Pharmaceuticals	17,862.04	18,454.73	15,011.19	17,862.04	15,011.19
	Chemicals	12,186.60	9,409.32	12,779.79	12,186.60	12,779.79
	Unallocated	37,656.69	40,382.76	33,896.24	37,656.69	33,896.24
	Total	67,605.23	69,246.81	61,687.22	67,605.23	61,687.22

- Notes:
- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 07 August 2017. These results have been subjected to "Limited Review" by the statutory auditors of the Company. The review report has been filed with stock exchange and is available on the Company's website.
 - The Company adopted Indian Accounting Standards ("Ind AS") from 01 January 2017, with transition date of 01 January 2016 and accordingly these results have been prepared in accordance with recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting prescribed under section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
 - Reconciliation of Net Profit as previously reported on account of transition from the previous GAAP to Ind AS for the quarter and half year ended 30 June 2016.

Rs. in lakhs		
Sr. No.	Particulars	
	Quarter ended 30 June 2016	Half year ended 30 June 2016
	1,790.22	3,014.80
a.	Difference in Provision for doubtful debts based on expected credit loss method under Ind AS 109	114.78
b.	Revenue recognition - measurement of revenue	525.24
c.	Other adjustments	(2.71)
d.	Physician samples- timing difference on recognition of expense	85.34
e.	Deferred tax on above adjustments	(250.09)
	2,262.78	3,088.34

4. Figures for the previous periods have been re-grouped/re-arranged wherever necessary.



Balance Sheet as at 30 June 2017

Particulars	As at 30.06.2017 Unaudited
ASSETS	
Non current Assets	
Property, plant and equipment	11,170.84
Capital work in progress	2,549.61
Other intangible assets	74.23
Financial assets	
i. Loans	15.79
ii. Others	679.66
Deferred tax assets (net)	2,689.22
Other non current assets	1,656.10
	18,735.45
Current assets	
Inventories	18,123.20
Financial Assets	
i. Investments	5,478.41
ii. Trade receivables	10,763.67
iii. Cash and cash equivalents	1,781.89
iv. Bank balance other than (ii) above	22,861.00
v. Loans	15.55
vi. Others	1,070.75
Other current assets	4,352.78
Current tax asset (Net)	6,134.11
Asset held for sale	699.45
	71,669.80
TOTAL ASSETS	90,305.25
EQUITY & LIABILITIES	
Equity	
Equity share capital	1,659.94
Other equity	65,945.29
	67,605.23
Non - Current liabilities	
Financial liabilities	
i. Other non-current financial liabilities	-
Provisions	2,623.89
Other non-current liabilities	564.33
	3,088.31
Current liabilities	
Financial liabilities	
i. Trade payables	9,487.10
ii. Other financial liabilities	4,035.54
Provisions	3,433.61
Other current liabilities	944.01
Current tax liabilities (net)	1,711.65
	19,611.71
TOTAL EQUITY & LIABILITIES	90,305.25

For Merck Limited

Anand Nambiar
Anand Nambiar
Managing Director

Limited Review Report on the Unaudited Financial Results for the quarter ended June 30, 2017 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors

Merck Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Merck Limited** ('the Company') for the quarter ended June 30, 2017 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standard and other recognised accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



HARIBHAKTI & CO. LLP


Chartered Accountants

4. The Company had prepared the unaudited financial results for quarter and half year ended June 30, 2016 in accordance with the Companies (Accounting Standards) Rules, 2006 referred to in Section 133 of the Act, on which B S R & Co. LLP, Chartered Accountants, the predecessor auditor, had issued an unmodified conclusion vide their report dated July 25, 2016. The financial information for the quarter and half year ended June 30, 2016 as included in this Statement are based on the previously reviewed financial results prepared in accordance with Companies (Accounting Standards) Rules, 2006 as adjusted for the differences in the accounting principles adopted by the Company on the transition to Ind AS, which have been reviewed by us. Our conclusion is not modified in respect of this matter.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048



Bhavik L. Shah

Partner

Membership No.122071



Place: Mumbai

Date: August 7, 2017